Elena Lopareva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elena Lopareva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Akihide Ryo
Department of Microbiology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan
1 shared publication - Bettina Bankamp
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Gimin Kim
Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
1 shared publication - Lijuan Hao
Centers for Disease Control and Prevention, 1600 Clifton Road N.E., Atlanta, GA 30329, USA
1 shared publication - Min-Hsin Chen
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
1 shared publication - Noriyuki Otsuki
Department of Virology 3, National Institute of Infectious Diseases, Musashimurayama 208-0011, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
Building Quality Control for Molecular Assays in the Global Measles and Rubella Laboratory Network
More than 100 laboratories in the World Health Organization Global Measles and Rubella Laboratory Network (GMRLN) perform nucleic acid-based methods for case confirmation of measles or rubella infections and/or strain surveillance (genotyping). The quality of laboratory data is critical to ensure that diagnostic results and country reports to regional verification committees are based on accurate data. A molecular External Quality Assurance (mEQA) program was initiated by the US-CDC in 2014 to evaluate the performance of laboratories in the network. The inclusion of testing for measles and rubella viruses, with a focus on detection and genotyping, plus the diversity of assays and platforms employed required a flexible and comprehensive proficiency testing program. A stepwise introduction of new evaluation criteria gradually increased the stringency of the proficiency testing program, while giving laboratories time to implement the required changes. The mEQA program plays an important role in many processes in the GMRLN, including informing plans for the training of laboratory staff, access to reagents, and the submission of sequence data to global databases. The EQA program for Local Public Health Institutes in Japan is described as an example for national mEQA programs. As more laboratories initiate molecular testing, the mEQA will need to continue to expand and to adapt to the changing landscape for molecular testing.
Open AccessBuilding Quality Control for Molecular Assays in the Global Measles and Rubella Laboratory Network
More than 100 laboratories in the World Health Organization Global Measles and Rubella Laboratory Network (GMRLN) perform nucleic acid-based methods for case confirmation of measles or rubella infections and/or strain surveillance (genotyping). The quality of laboratory data is critical to ensure that diagnostic results and country reports to regional verification committees are based on accurate data. A molecular External Quality Assurance (mEQA) program was initiated by the US-CDC in 2014 to evaluate the performance of laboratories in the network. The inclusion of testing for measles and rubella viruses, with a focus on detection and genotyping, plus the diversity of assays and platforms employed required a flexible and comprehensive proficiency testing program. A stepwise introduction of new evaluation criteria gradually increased the stringency of the proficiency testing program, while giving laboratories time to implement the required changes. The mEQA program plays an important role in many processes in the GMRLN, including informing plans for the training of laboratory staff, access to reagents, and the submission of sequence data to global databases. The EQA program for Local Public Health Institutes in Japan is described as an example for national mEQA programs. As more laboratories initiate molecular testing, the mEQA will need to continue to expand and to adapt to the changing landscape for molecular testing.